UBS initiated coverage of Treace Medical with a Buy rating and $24 price target. Treance Medical can sustain strong double-digit sales growth through at least 2027 as the company ramps adoption of its clinically proven, more effective lapiplasty into the existing 450k procedure and $2.3B bunion surgery market, the analyst tells investors in a research note, adding that the firm’s already above-consensus sales estimates for 2024 and 2025 are likely conservative.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on TMCI:
- Treace Medical announces updated ALIGN3D study data at AOFAS Meeting 2023
- Treace Highlights New Product Innovations and Updated ALIGN3D™ Clinical Study Data at the American Orthopaedic Foot & Ankle Society Annual Meeting 2023
- Treace Medical Concepts Announces New Patent Covering Instrumented Bunion Correction Procedures and Milestone 50th U.S. Patent
- Treace Medical announces new patent covering bunion correction procedures
- Treace announces release of new complementary technologies for bunions